Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Lucid is a commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer (specifically esophageal adenocarcinoma) in patients with gastroesophageal reflux disease (GERD). Its flagship product is the EsoGuard Esophageal DNA Test, performed on samples collected via the EsoCheck device. The Company is a non-consolidated subsidiary of PAVmed Inc.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $1,172 | $783 | $3,149 | $1,388 |
| Cost of Revenue | $1,684 | $1,634 | $4,954 | $4,522 |
| Gross Profit (Loss) | $(512) | $(851) | $(1,805) | $(3,134) |
| Operating Loss | $(11,694) | $(11,128) | $(33,677) | $(37,029) |
| Net Loss | $(12,371) | $(14,208) | $(33,988) | $(41,836) |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.34) | $(0.87) | $(1.01) |
| Cash and Equivalents (End of Period) | $14,489 | $24,050 | $14,489 | $24,050 |
| Working Capital | $2,575 | $(7,309) | $2,575 | $(7,309) |
| Senior Secured Convertible Note (Fair Value) | $10,200 | $14,490 | $10,200 | $14,490 |
Note: Working Capital is calculated as Total Current Assets ($16,824) minus Total Current Liabilities ($14,249) as of September 30, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 50% year-over-year for Q3 2024 ($1.17M vs. $0.78M) and 127% for the nine-month period ($3.15M vs. $1.39M), driven by increased volume of EsoGuard tests.
- Operating Expenses: Total operating expenses decreased slightly for the nine months ended Sept 30, 2024 ($36.8M) compared to the prior year ($38.4M), primarily due to a reduction in amortization of acquired intangible assets ($0.6M vs. $1.5M) and lower R&D costs.
- Debt Fair Value: The fair value of the Senior Secured Convertible Note decreased from $13.95M at year-end 2023 to $10.20M at Sept 30, 2024, resulting in a non-cash gain of $0.57M for the nine-month period (compared to a loss of $3.52M in the prior year).
- Equity Transactions: The Company raised approximately $29.8M in gross proceeds through Series B and Series B-1 Preferred Stock offerings in March and May 2024. Additionally, a $7.5M deemed dividend was recorded due to the exchange of Series A/A-1 preferred stock for Series B preferred stock.
Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for 12 months beyond the issuance date. Continued operations depend on obtaining third-party reimbursement coverage for EsoGuard and raising additional capital.
- Debt Refinancing: On November 8, 2024, the Company notified the holder of its March 2023 Senior Convertible Note of its intent to redeem the note. To fund this, the Company entered into agreements to issue new 12.0% senior secured convertible notes due 2029, having received $7.7M in proceeds as of the filing date.
- NASDAQ Compliance: The Company received notice in June 2024 that its stock price fell below the $1.00 minimum bid price requirement. It has 180 days (until December 18, 2024) to regain compliance.
- Related Party Transactions: The Company pays a Management Services Agreement (MSA) fee to PAVmed Inc., which increased to $1.05M per month effective July 1, 2024. A significant portion of prior MSA fees was settled via the issuance of common stock.
- Regulatory: The FDA's final rule on Laboratory Developed Tests (LDTs) does not immediately impact EsoGuard as it was marketed prior to the cutoff date and is NYS CLEP-approved.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $14.5M cash balance against the burn rate of ~$34M over nine months and the timeline for reimbursement approvals.
- Debt Redemption: Confirm the successful closing of the November 2024 Senior Convertible Notes to refinance the March 2023 Note and avoid default.
- Reimbursement Status: Monitor progress on Medicare (MolDX) and private payer coverage for the EsoGuard test, which is critical for revenue scalability.
- NASDAQ Listing: Track the stock price to ensure it meets the $1.00 minimum bid requirement by December 18, 2024, to avoid delisting.
- PAVmed Relationship: Assess the impact of the increased MSA fees ($1.05M/month) on future operating expenses and cash flow.